Endo Withdraws Opana Painkiller From Market at FDA’s Request Post author:Sam Post published:July 6, 2017 Post category:Drug Industry Daily Endo will withdraw Opana ER from the market, following an FDA request in June. Source: Drug Industry Daily You Might Also Like FDA Releases Final Guidance on Submitting Promotional Materials Both Electronically and Otherwise April 12, 2022 Amgen Asks Court to Scuttle Genentech’s Defense of Avastin Patents October 9, 2017 LumanLab, University Researchers Partner on AI to Detect and Assess Autism May 25, 2023
FDA Releases Final Guidance on Submitting Promotional Materials Both Electronically and Otherwise April 12, 2022